OCT 26, 2016 07:30 PM PDT

Uniting the Two Arms of the Immune System to Fight Cancer

WRITTEN BY: Kara Marker
The newest effort in cancer treatment research involves the combination of not one, not two, not three, but four different cancer immunotherapies to kill tumor cells. So far in mice studies with extremely aggressive cancer, the combination treatment has been 75 percent effective.
T cells are key to the adaptive immune response. In this image, the top row shows few T cells in untreated mice, while the bottom rows show many T cells produced after immunotherapy treatment. Credit: MIT
Two scientists from the Massachusetts Institute of Technology (MIT) have brought their research together to make a cancer therapy juggernaut. First, MIT’s Dane Wittrup, PhD, studied the deliverance of antibodies and a signaling molecule called interleukin-2 (IL-2) that enhances the immune response in mice. The treatment stopped the growth of aggressive melanoma tumors in mice for as long as they received treatment. Plus, Wittrup’s findings appeared to be even more successfully when the researchers added T cells to be delivered along with antibodies and IL-2, stimulating the adaptive immune system.

Then, MIT’s Darrell Irvine, PhD, studied a novel T cell “vaccine” that attaches to lymph nodes via a protein called albumin. Once linked to the lymph nodes, the T cell vaccine stimulates large production of T cells to gang up against the tumor cells.

Once Irvine and Wittrup combined their experimental treatments, they quickly saw both powerhouses of the immune system become activated, the adaptive and the innate responses. Their findings showed that the new therapy has the potential to treat multiple types of human cancer, and it is also possible that the treatment could trigger immune memory so lymphocytes could “remember” the right cancer cells to target and kill if the tumor continues to grow.

"We wondered if we could bring these two [therapies] together and try to generate a more integrated immune response that would bring together all arms of the immune system against the tumor,” Irvine said.

The result of combining the two therapies was a four-part anti-cancer response:
  1. Antibody targeted tumor and recruited additional immune cells to help activate T cells
  2. Vaccine targeted tumor and stimulated the proliferation of T cells to attack the tumor
  3. IL-2 helped the T cell population expand quickly
  4. Anti-PD1 molecule blocked PD1, a receptor found on T cells, so the lymphocytes would stay active longer
They tested the combination treatment in mice implanted with three different types of tumors: melanoma, lymphoma, and breast cancer. These engineered cancers are harder to treat than human tumors implanted in mice because they suppress the immune system.

Overall, no matter what time of tumor the mice were implanted with, the researchers saw a general trend of tumor elimination: just about 75 percent of the tumors were completely destroyed. To confirm the staying power of the treatment, the researchers implanted more tumor cells into the same mice that had cleared their cancer. Their immune systems were once again able to eliminate all of the tumor cells.

"We have shown that with the right combination of signals, the endogenous immune system can routinely overcome large immunosuppressive tumors, which was an unanswered question," said Irvine.

While cancer treatments in the past were often thwarted by the ability of tumor cells to secrete chemicals to remain invisible to the immune system, scientists are hoping to get the immune cells back online with the new combination treatment from MIT.

"To our knowledge, nobody has been able to take tumors that big and cure them with a therapy consisting entirely of injecting biomolecular drugs instead of transplanting T cells," Wittrup said.

In the future, Wittrup, Irvine, and others from MIT plan on designing the combination treatment to treat both specific cases of cancer and broad cases of cancerous growth. Their current study was published in the journal Nature Medicine.

Source: Massachusetts Institute of Technology
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 15, 2019
Health & Medicine
NOV 15, 2019
A Second Patient Cured of HIV: Are We Close to a Cure for Everyone Infected?
There is a consensus that the first HIV infection occurred in the 1920s in Kinshasa, the Democratic Republic of Congo when it was passed to human...
NOV 15, 2019
Health & Medicine
NOV 15, 2019
Tick-Borne Diseases Are Rapidly Rising in the U.S.
Tick-borne diseases have significantly increased in the U.S. in the past few years. In 2016 there were 48,610 reported cases and in 2017 59,349; these...
NOV 15, 2019
NOV 15, 2019
Widely Prescribed Breast Cancer Medication Promotes Metastasis
The primary goals of metastatic breast cancer treatment are to ensure that the patient has the longest survival possible while experiencing the highes...
NOV 15, 2019
NOV 15, 2019
Flu Shot Less Effective Due to Overuse of Antibioitics
New research out of the Stanford University School of Medicine shows that the consequence of overuse of antibiotics lowers the effectiveness of the seasona...
NOV 15, 2019
NOV 15, 2019
Diseases We Share with Our Canine Companions: Autoimmune Encephalitis in Dogs
Like humans, dogs can develop autoimmune encephalitis, and it’s common - mostly affecting smaller breeds and young adult dogs. Now scientists underst...
NOV 15, 2019
Drug Discovery & Development
NOV 15, 2019
AI Exponentially Accelerates Drug Development
Research and development for new drugs is both an expensive and lengthy process, often lasting years, if not decades. With the development of artificial in...
Loading Comments...